127094-78-4

Basic information

• Product Name: 5-(2,4-DIFLUORO-PHENYL)-FURAN-2-CARBALDEHYDE
• Synonyms: TIMTEC-BB SBB011184;5-(2,4-DIFLUORO-PHENYL)-FURAN-2-CARBALDEHYDE
• CAS NO: 127094-78-4
• Molecular Formula: C11H6F2O2
• Molecular Weight: 208.16
• Mol File: 127094-78-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(2,4-DIFLUORO-PHENYL)-FURAN-2-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2,4-DIFLUORO-PHENYL)-FURAN-2-CARBALDEHYDE(127094-78-4)
• EPA Substance Registry System: 5-(2,4-DIFLUORO-PHENYL)-FURAN-2-CARBALDEHYDE(127094-78-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 127094-78-4(Hazardous Substances Data)

Upstream product

• 27329-70-0 5-formylfurane-2-boronic acid 
• 348-57-2 2,4-difluorobromobenzene 
• 367-25-9 2,4-difluorophenylamine 
• 98-01-1 furfural 
• 45768-10-3 2,4-Difluor-benzoldiazonium 

Downstream Products

• 1489176-43-3 C₂₁H₁₅ClF₂N₄O₃*ClH 
• 1032337-94-2 C₁₉H₁₁F₄NO₄ 
• 1022400-13-0 C₁₁H₈F₂O₂ 
• 1032338-16-1 C₁₉H₁₁Cl₂F₂NO₄ 

Relevant articles and documents

TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE

The invention provides a variety of compounds having the structure of Formula I and uses of such compounds for treatment of various indications, including cancer as well as methods of treatment involving such compounds are also provided. The uses of the compounds may specifically include: bladder cancer, cholangiocarcinoma; colorectal cancer; diffuse large B-cell lymphoma (DLBC); liver cancer; ovarian cancer; thymoma; thyroid cancer; clear cell renal cell carcinoma (CCRCC); chromophobe renal cell carcinoma (ChRCC); prostate cancer; breast cancer; uterine cancer; pancreatic cancer; cervical cancer; uveal melanoma; acute myeloid leukemia (AML); head and neck cancer; small cell lung cancer (SCLC); lung adenocarcinoma sarcoma; mesothelioma; adenoid cystic carcinoma (ACC), sarcoma; testicular germ cell cancer; uterine cancer; pheochromocytoma and paraganglioma (PCPG); melanoma; glioma; glioblastoma multiforme; T-cell Acute Lymphoblastic Leukemia; T-cell Lympohoma, medulloblastoma; and neuroblastoma.

New class of potent antitumor acylhydrazone derivatives containing furan

A pair of chemical isomeric structures of N-acylhydrazone compounds I and II were designed and synthesized. The reaction was carried out with high diastereoselectivity to obtain one configurational isomer in excellent yields. The exact configuration and conformation of IIa and IIe were confirmed by the X-ray single crystal diffraction. The antitumor bioassay revealed that some compounds exhibited excellent activity against the selected cancer cell lines. In particular, IIf (IC50 = 16.4 μM) was better than doxorubicin (IC50 = 53.3 μM) against human promyelocytic leukemic cells (HL-60). Their toxicities were predicted in silico. The results showed that compounds II were safe and eligible to be development candidates. IIf showed great promise as a novel lead compound for further anticancer discovery.

CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS

Disclosed are methods for the prevention or treatment of tuberculosis in a subject infected with Mycobacterium tuberculosis by administering rhodanine derivatives of formula (I), as well as some novel such compounds. Other embodiments are also disclosed.